There are several recurrent molecular and histological characteristics that were observed in an increasing number of investigations around FGFR3-TACC3 fusion-positive glioma: even in studies that were not limited to IDH-wildtype or former primary glioblastomas WHO grade 4, but included all forms of malignant gliomas, all gliomas that were positive for a FGFR3-TACC fusion presented the wildtype version of the IDH1 and IDH2 gene [10,20,31,58,60,81,84]. This evidence concerns the gene IDH2 and central nervous system cancer.